<DOC>
	<DOCNO>NCT01294683</DOCNO>
	<brief_summary>This study do find tablet contain extended release ( ER ) niacin , laropiprant , simvastatin ( ERN/LRPT/SIM ) effective tablet contain ER niacin laropiprant take simvastatin tablet ( ERN/LRPT + SIM ) lower high cholesterol high lipid level blood . The primary hypothesis ERN/LRPT/SIM 2 g/40 mg equivalent ERN/LRPT 2 g co-administered simvastatin 40 mg reduce low-density lipoprotein cholesterol ( LDL-C ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Extended-Release Niacin + Laropiprant + Simvastatin Participants With Primary Hypercholesterolemia Mixed Dyslipidemia ( MK-0524B-118 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Inclusion criterion Participant history primary hypercholesterolemia mixed dyslipidemia meet LDLC triglyceride criterion . Visit 2 : Participant high risk coronary heart disease ( CHD ) CHD riskequivalent . Exclusion Criteria Participant pregnant breastfeeding , expect conceive study . Participant history malignancy . Participant consume 3 alcoholic drink per day ( 14 per week ) . Participant high risk CHD patient statin therapy patient statin therapy equivalent 80 mg simvastatin . Participant Type 1 Type 2 diabetes mellitus poorly control , statin therapy . Participant currently engage vigorous exercise aggressive diet regimen . Participant uncontrolled endocrine metabolic disease , uncontrolled gout , kidney hepatic disease , heart failure , recent peptic ulcer disease , hypersensitivity allergic reaction niacin simvastatin , recent heart attack , stroke heart surgery . Participant human immunodeficiency virus ( HIV ) positive . Participant take niacin &gt; 50 mg/day , bileacid sequestrants , hydroxymethyl glutaryl coenzyme A ( HMGCoA ) reductase inhibitor , ezetimibe , Cholestinâ„¢ [ red yeast rice ] red yeast product within 6 week , fibrates within 8 week randomization visit ( Visit 3 ) . Note : Fish oil , phytosterol margarine nonprescribed therapy allow provided participant stable dose 6 week prior Visit 2 agrees remain dose duration study . Participant currently receive cyclical hormonal contraceptive intermittent use hormone replacement therapy ( HRTs ) ( e.g. , estradiol , medroxyprogesterone , progesterone ) . Note : Participants stable dose noncyclical HRT hormonal contraceptive great 6 week prior Visit 1 eligible agree remain regimen duration study . Participant take prohibited medication systemic corticosteroid , itraconazole ketoconazole , erythromycin , clarithromycin , telithromycin , nefazodone , HIV protease inhibitor , verapamil , amiodarone , cyclosporine , danazol , diltiazem fusidic acid . Participant consume &gt; 1 quart grapefruit juice/day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Low-density lipoprotein</keyword>
	<keyword>LDL</keyword>
	<keyword>High-density lipoprotein</keyword>
	<keyword>HDL</keyword>
	<keyword>Niacin</keyword>
	<keyword>Lipid modifying therapy</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>High cholesterol</keyword>
	<keyword>Triglycerides</keyword>
	<keyword>Mixed Dyslipidemia</keyword>
</DOC>